TRAIL R1/DR4/TNFRSF10A Protein, Human, Recombinant (hFc)

Catalog No. TMPK-00708 Copy Product Info

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis selectively via its interaction with the death receptors TRAILR1/DR4 and TRAILR2/DR5 in a wide range of cancers, while sparing normal cells. Despite its tremendous potential for cancer therapeutics, the translation of TRAIL into the clinic has been confounded by TRAIL-resistant cancer populations.

TRAIL R1/DR4/TNFRSF10A Protein, Human, Recombinant (hFc)

Catalog No. TMPK-00708

Copy Product Info

TRAIL R1/DR4/TNFRSF10A Protein, Human, Recombinant (hFc)

Pack Size	Price	USA Stock	Global Stock
5 μg	$43	7-10 days	7-10 days
10 μg	$66	7-10 days	7-10 days
20 μg	$105	7-10 days	7-10 days
50 μg	$197	7-10 days	7-10 days
100 μg	$336	7-10 days	7-10 days
200 μg	$596	7-10 days	7-10 days
500 μg	$1,350	7-10 days	7-10 days

Add to Cart

Add to Quotation

For In stock only · Estimated delivery:USA Stock (1-2 days) Global Stock (5-7 days)

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Resource Download

User Guide of Recombinant Proteins

Product Information

Biological Activity	Immobilized Human TRAIL, No Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Human TRAIL R1, hFc Tag with the EC50 of 51.6ng/ml determined by ELISA.
Description	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis selectively via its interaction with the death receptors TRAILR1/DR4 and TRAILR2/DR5 in a wide range of cancers, while sparing normal cells. Despite its tremendous potential for cancer therapeutics, the translation of TRAIL into the clinic has been confounded by TRAIL-resistant cancer populations.
Species	Human
Expression System	HEK293 Cells
Tag	C-hFc
Accession Number	O00220
Synonyms	TRAIL-R,TRAIL R1,TNFRSF10A,MGC9365,DR4,CD261,APO2
Construction	Pro34-Asn239
Protein Purity	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Molecular Weight	48.8 kDa (predicted). Due to glycosylation, the protein migrates to 50-60 kDa based on Tris-Bis PAGE result.
Endotoxin	< 1.0 EU/μg of the protein as determined by the LAL method.
Formulation	Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.
Reconstitution	Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.
Stability & Storage	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
Shipping	In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.
Research Background	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis selectively via its interaction with the death receptors TRAILR1/DR4 and TRAILR2/DR5 in a wide range of cancers, while sparing normal cells. Despite its tremendous potential for cancer therapeutics, the translation of TRAIL into the clinic has been confounded by TRAIL-resistant cancer populations.